Abelacimab Reduces Bleeding Events in Patients With Atrial Fibrillation

Anthos Therapeutics recently announced positive primary data from the AZALEA-TIMI 71 study of patients with atrial fibrillation at moderate to high risk of stroke. The results, which were presented as a late-breaking abstract at the American Heart Association’s Scientific Sessions 2023, showed an overwhelmingly greater-than-anticipated reduction in major and clinically relevant nonmajor bleeds using abelacimab therapy.

Abelacimab is a novel, highly selective, fully human monoclonal antibody that locks Factor XI in the inactive state, resulting in dual inhibitory activity against both Factor XI and its activated form, Factor XIa.

DocWire News spoke with Dr. Christian T. Ruff, principal investigator of the AZALEA-TIMI 71 study, about the exciting results and the significance of the findings for physicians.